Loading...
Radiopharm Theranostics Limited
RAD.AX•ASX
Healthcare
Biotechnology
A$0.02
A$0.00(0.00%)
Radiopharm Theranostics Limited (RAD.AX) Financial Performance & Income Statement Overview
Review Radiopharm Theranostics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
2.35%
↑ 2.35%
Operating Income Growth
9.11%
↑ 9.11%
Net Income Growth
-38.54%
↓ 38.54%
Operating Cash Flow Growth
0.97%
↑ 0.97%
Operating Margin
-2810.80%
↓ 2810.80%
Gross Margin
-1233.93%
↓ 1233.93%
Net Profit Margin
-3028.64%
↓ 3028.64%
ROE
-103.08%
↓ 103.08%
ROIC
-49.05%
↓ 49.05%
Radiopharm Theranostics Limited (RAD.AX) Income Statement & Financial Overview
Review Radiopharm Theranostics Limited's (RAD.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | -$1.05M | $2.03M | $973993.00 | $973993.00 |
| Cost of Revenue | $3.25M | $1.57M | $4.75M | $5.05M |
| Gross Profit | -$4.31M | $462966.00 | -$3.77M | -$4.07M |
| Gross Profit Ratio | $4.09 | $0.23 | -$3.87 | -$4.18 |
| R&D Expenses | $7.99M | $15.10M | $15.88M | $7.94M |
| SG&A Expenses | $6.09M | $6.46M | $3.67M | $4.21M |
| Operating Expenses | $14.09M | $21.56M | $19.55M | $7.24M |
| Total Costs & Expenses | $15.63M | $23.13M | $24.29M | $12.28M |
| Interest Income | $0.00 | $0.00 | $279103.00 | $279103.00 |
| Interest Expense | $605913.00 | $36975.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.55M | $1.57M | $4.75M | $825865.00 |
| EBITDA | -$18.24M | -$27.14M | -$19.32M | -$7.46M |
| EBITDA Ratio | $17.32 | -$10.61 | -$20.07 | -$7.65 |
| Operating Income | -$19.36M | -$23.13M | -$24.29M | -$8.28M |
| Operating Income Ratio | $18.38 | -$11.38 | -$24.94 | -$8.50 |
| Other Income/Expenses (Net) | -$1.03M | -$5.62M | $231427.00 | $206585.00 |
| Income Before Tax | -$20.39M | -$28.75M | -$24.06M | -$11.03M |
| Income Before Tax Ratio | $19.36 | -$14.15 | -$24.71 | -$11.33 |
| Income Tax Expense | $2.80M | -$3.99M | -$2.005M | $1519.00 |
| Net Income | -$23.19M | -$24.76M | -$22.06M | -$11.03M |
| Net Income Ratio | $22.02 | -$12.18 | -$22.65 | -$11.32 |
| EPS | -$0.06 | -$0.07 | -$0.06 | -$0.03 |
| Diluted EPS | -$0.06 | -$0.07 | -$0.06 | -$0.03 |
| Weighted Avg Shares Outstanding | $364.87M | $343.28M | $359.27M | $335.03M |
| Weighted Avg Shares Outstanding (Diluted) | $364.87M | $343.28M | $359.27M | $335.02M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan